September 2, 2020
NeuroPace, the maker of an implanted neurostimulation therapy device for uncontrolled epileptic seizures, announced a $33 million equity raise on Monday. Accelmed Partners led the investment, which was joined by new backers such as Revelation Partners, Soleus Capital and an unnamed strategic investor. Prior backers KCK Group and OrbiMed Advisors also contributed.
Alongside the equity, NeuroPace...
November 13, 2019
Japanese pharma Eisai Co.'s subsidiary Eisai Inc. is rolling out a new skill on Amazon Alexa developed specifically to target children with Lennox-Gastaut Syndrome (LGS), a rare and severe form of epilepsy.
Dubbed Ella the Jellyfish, the underwater-themed platform includes interactive games such as "Freeze Dance" and "Color Hunt." It also provides users access to music and meditation services. ...
July 8, 2019
Pharmaceutical company UCB and DEARhealth, a disease management software company, are joining forces on a new initiative aimed at predicting health outcomes for patients with epilepsy. The pair will use DEARhealth’s platform, which integrates artificial intelligence with EHRs.
“This technology will ensure that specific subpopulations within epilepsy will all receive the specific care needed for...
January 11, 2019
The Embrace2, a seizure monitoring wearable from Boston and Milan-based Embrace, has received an updated FDA clearance that allows it to be used by children ages six and up — the first such device to receive clearance for pediatric use.
"The fact that this is the first clearance of its kind in epilepsy highlights how difficult it is to get robust results with pediatric patients in a clinical...
October 29, 2018
A new study in the journal Neurology shows that the NightWatch, a connected armband from Leiden, Netherlands-based LivAssured, detected nighttime epileptic seizures 85 percent of the time.
The device has been under development for 20 years by a consortium that includes Kempenhaeghe epilepsy centre, Eindhoven University of Technology, the Foundation for Epilepsy Institutions in the Netherlands (...
June 28, 2018
Over a year ago Partners Health and biopharmaceutical company UCB teamed up to tackle a moonshot goal: make Boston the best city to live in for people with epilepsy. So the team decided that in order to design a digital health platform to support this task, it was vital to go to patients for input and ideas.
“We want to be patient centric, but what does patient centric mean?” Dr. Kamal Jethwani...
February 5, 2018
Empatica's Embrace, the consumer-facing wearable for epileptic seizure detection, received 510(k) clearance from the FDA last month. The wearable, which has already been used in clinical trials by pharma company Sunovion, has a long history that's led it up to this milestone.
The clearance is as a prescription, not an over-the-counter device, which means users will have to secure a prescription...
October 10, 2017
London-based medical device manufacturer LivaNova has announced FDA approval of its most recent Vagus Nerve Stimulation Therapy (VNS Therapy) System, which will be the smallest and lightest responsive therapy available for drug-resistant epilepsy patients aged four years and older.
The treatment consists of the new SenTiva implantable generator, the VNS Therapy Programming System, a wireless wand...
August 17, 2017
UCB, a global pharmaceutical company, is partnering with Belgian American health startup Byteflies to use the startup's wearable sensors to monitor seizures.
Byteflies makes a customizable wearable device for the pharma and healthcare industries called Sensor Dot. It's a quarter-sized sensor that can be worn around the wrist or attached anywhere on the body as a patch. It's capable of measuring ...
December 5, 2016
Marlborough, Massachusetts-based pharma company Sunovion will use the Empatica Embrace, a wearable device for seizure detection, in a phase 4 clinical study of Aptiom, a drug meant to reduce seizures in people with epilepsy.
“We believe that incorporating digital health technologies into traditional treatment paradigms has the potential to inform and enhance best practices and further empower...